Semaglutide, a GLP-1 receptor agonist, is primarily used for the treatment of type 2 diabetes (T2DM) due to its potent antidiabetic effects. However, recent research highlights its potential anti-inflammatory properties, which may offer additional benefits in managing diabetic complications. Chronic hyperglycemia in diabetes is associated with increased inflammation, which contributes to insulin resistance and various complications, including cardiovascular disease, diabetic nephropathy, and neuropathy. Semaglutide has been shown to reduce inflammatory cytokines such as TNF-α and IL-6, and modulate immune responses, potentially reducing inflammation in tissues like the liver, kidneys, and cardiovascular system. Mechanistically, semaglutide may exert anti-inflammatory effects by inhibiting inflammatory pathways, reducing oxidative stress, and modulating immune cell activity. Clinical studies suggest that semaglutide can improve renal function in T2DM patients and may have greater anti-inflammatory potential compared to other GLP-1 mimetics, particularly in the context of COVID-19. Additionally, semaglutide has been shown to reduce atherosclerosis and improve vascular function, indicating its potential protective role in the cardiovascular system. While the exact mechanisms of semaglutide's anti-inflammatory effects are not fully understood, current evidence suggests that it can reduce inflammatory responses through multiple pathways, including the modulation of immune cell activity and the suppression of inflammatory cytokines. These findings suggest that semaglutide may provide cardiovascular and hepatic benefits beyond its established antidiabetic effects. Further research is needed to fully elucidate the mechanisms and potential therapeutic applications of semaglutide in inflammation-related diseases.Semaglutide, a GLP-1 receptor agonist, is primarily used for the treatment of type 2 diabetes (T2DM) due to its potent antidiabetic effects. However, recent research highlights its potential anti-inflammatory properties, which may offer additional benefits in managing diabetic complications. Chronic hyperglycemia in diabetes is associated with increased inflammation, which contributes to insulin resistance and various complications, including cardiovascular disease, diabetic nephropathy, and neuropathy. Semaglutide has been shown to reduce inflammatory cytokines such as TNF-α and IL-6, and modulate immune responses, potentially reducing inflammation in tissues like the liver, kidneys, and cardiovascular system. Mechanistically, semaglutide may exert anti-inflammatory effects by inhibiting inflammatory pathways, reducing oxidative stress, and modulating immune cell activity. Clinical studies suggest that semaglutide can improve renal function in T2DM patients and may have greater anti-inflammatory potential compared to other GLP-1 mimetics, particularly in the context of COVID-19. Additionally, semaglutide has been shown to reduce atherosclerosis and improve vascular function, indicating its potential protective role in the cardiovascular system. While the exact mechanisms of semaglutide's anti-inflammatory effects are not fully understood, current evidence suggests that it can reduce inflammatory responses through multiple pathways, including the modulation of immune cell activity and the suppression of inflammatory cytokines. These findings suggest that semaglutide may provide cardiovascular and hepatic benefits beyond its established antidiabetic effects. Further research is needed to fully elucidate the mechanisms and potential therapeutic applications of semaglutide in inflammation-related diseases.